glycopyrrolate has been researched along with Disease Exacerbation in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (76.47) | 24.3611 |
| 2020's | 4 (23.53) | 2.80 |
| Authors | Studies |
|---|---|
| Alcazar, B; Barrecheguren, M; Kostikas, K; Mezzi, K; Miravitlles, M; Shen, S; Soler-Cataluña, JJ; Wedzicha, JA | 1 |
| Banerji, D; Frent, SM; Gupta, P; Kostikas, K; Mackay, AJ; Olsson, P; Patalano, F; Pfister, P; Roche, N; Wedzicha, JA | 1 |
| Marth, K; Pohl, W; Renner, A | 1 |
| Cheng, SH; Hsu, YJ; Huang, YL; Lai, JH; Lin, CW; Liou, JT; Pan, HY; Tsai, CL; Wang, MT | 1 |
| Aalamian-Mattheis, M; Castellani, W; Clemens, A; Gaga, M; Greulich, T; Kostikas, K; Lane, S; Marin, JM; Ninane, V; Nunez, X; Patalano, F; Vogelmeier, CF | 1 |
| Criner, GJ; Dhungana, S | 1 |
| Buhl, R; Criée, CP; Kardos, P; Lossi, NS; Vogelmeier, CF; Worth, H | 1 |
| Corradi, M; Papi, A; Petruzzelli, S; Scuri, M; Singh, D; Spinola, M; Usmani, OS; Vestbo, J | 1 |
| Anzueto, AR; Banerji, D; Fogel, R; Kostikas, K; Larbig, M; Mezzi, K; Patalano, F; Shen, S; Wedzicha, JA | 1 |
| Banerji, D; Chapman, KR; Fogel, R; Frent, SM; Gutzwiller, FS; Kostikas, K; Larbig, M; Mackay, A; Patalano, F; Shen, S; Wedzicha, JA | 1 |
| Blasi, F; Mantero, M; Radovanovic, D; Santus, P | 1 |
| Fogel, R; Fucile, S; Goyal, P; Jenkins, C; Kostikas, K; Mezzi, K; Shen, S; Singh, D; Tsiligianni, I; Wedzicha, JA | 1 |
| Wise, J | 1 |
| Arrasate, C; Banerji, D; Chen, H; D'Andrea, P; Decramer, M; Ficker, JH; Niewoehner, DE; Sandström, T; Taylor, AF; Wedzicha, JA | 1 |
| Banerji, D; Bateman, ED; Mahler, DA; Patalano, F; Vogelmeier, CF; Wedzicha, JA | 1 |
| Ulrik, CS | 1 |
| Einecke, D | 1 |
5 review(s) available for glycopyrrolate and Disease Exacerbation
| Article | Year |
|---|---|
Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Drug Combinations; Forced Expiratory Volume; Formoterol Fumarate; Glycopyrrolate; Humans; Lung; Metered Dose Inhalers; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Time Factors; Treatment Outcome | 2017 |
Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Beclomethasone; Bronchodilator Agents; Disease Progression; Drug Combinations; Evidence-Based Medicine; Exercise Tolerance; Forced Expiratory Volume; Formoterol Fumarate; Glucocorticoids; Glycopyrrolate; Humans; Lung; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Recovery of Function; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Beclomethasone; Bronchodilator Agents; Disease Progression; Drug Therapy, Combination; Formoterol Fumarate; Glucocorticoids; Glycopyrrolate; Humans; Pulmonary Disease, Chronic Obstructive; Quality of Life; Randomized Controlled Trials as Topic | 2018 |
Recent advances in COPD disease management with fixed-dose long-acting combination therapies.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Disease Management; Disease Progression; Drug Combinations; Ethanolamines; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome | 2014 |
[The combination of indacaterol and glycopyrronium has effects on symptoms, lung function, and rate of exacerbations in COPD patients].
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Disease Progression; Drug Combinations; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones | 2014 |
6 trial(s) available for glycopyrrolate and Disease Exacerbation
| Article | Year |
|---|---|
Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study.
Topics: Aged; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glycopyrrolate; Health Status; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Surveys and Questionnaires | 2020 |
Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Bronchodilator Agents; Disease Progression; Drug Combinations; Drug Substitution; Dyspnea; Europe; Female; Forced Expiratory Volume; Glycopyrrolate; Health Status; Humans; Indans; Lung; Male; Middle Aged; Muscarinic Antagonists; Patient Safety; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Recovery of Function; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2017 |
Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.
Topics: Aged; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones | 2018 |
Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME.
Topics: Bronchodilator Agents; Disease Progression; Drug Therapy, Combination; Female; Fluticasone; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Risk Factors; Salmeterol Xinafoate; Surveys and Questionnaires | 2019 |
Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study.
Topics: Aged; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Sex Characteristics; Treatment Outcome | 2019 |
Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Monitoring; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; Respiratory System; Scopolamine Derivatives; Severity of Illness Index; Tiotropium Bromide; Treatment Outcome | 2013 |
6 other study(ies) available for glycopyrrolate and Disease Exacerbation
| Article | Year |
|---|---|
COPD clinical control as a predictor of future exacerbations: concept validation in the SPARK study population.
Topics: Aged; Bronchodilator Agents; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones; Reproducibility of Results; Respiratory Function Tests; Risk Assessment; Severity of Illness Index; Tiotropium Bromide; Treatment Outcome | 2020 |
TRICOP - A Real-world effectiveness study with a single-inhaler extrafine triple therapy over 52 weeks in Austrian patients with COPD.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Austria; Beclomethasone; Disease Progression; Drug Therapy, Combination; Female; Formoterol Fumarate; Glycopyrrolate; Humans; Male; Middle Aged; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Time Factors; Treatment Outcome | 2021 |
Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Beclomethasone; Benzyl Alcohols; Budesonide, Formoterol Fumarate Drug Combination; Chlorobenzenes; Cohort Studies; Comparative Effectiveness Research; Disease Progression; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Formoterol Fumarate; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pneumonia; Propensity Score; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines | 2021 |
GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Critical Pathways; Disease Management; Disease Progression; Drug Combinations; Drug Therapy, Combination; Female; Germany; Glycopyrrolate; Humans; Indans; Longitudinal Studies; Maintenance Chemotherapy; Male; Middle Aged; Muscarinic Antagonists; Practice Guidelines as Topic; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones | 2017 |
Novartis found to be in breach of code over drug brochure.
Topics: Advertising; Codes of Ethics; Disease Progression; Drug Industry; Drug Labeling; Female; Glycopyrrolate; Humans; Male; Pamphlets; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive | 2013 |
[Narrowing indications for inhaled steroids in COPD].
Topics: Bronchodilator Agents; Clinical Trials as Topic; Disease Progression; Drug Combinations; Glycopyrrolate; Humans; Indans; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |